Understanding these pathways, and the identification of the key proteins that control the ability of cancer cells to reprogram their metabolism through biochemical, and
epigenetic or genetic
alterations that make them resistant to therapies, is of paramount importance for the design of more
targeted and therefore less toxic therapies.